CD147 and VEGF Expression in Advanced Renal Cell Carcinoma and Their Prognostic Value

Liang, Yu‐Xiang; He, Hui‐Chan; Han, Zhengxue; Bi, Xiangjun; Dai, Qi-Shan; Ye, Yongkang; Qin, Weijun; Zeng, Guohua; Zhu, Gang; Xu, Chuanliang; Zhong, Weide

doi:10.1080/07357900802709167

Cited by 56 publications

(54 citation statements)

References 23 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In order to identify the association of JMJD1A and renal cell carcinoma, we first measured the VEGFA and GLUT1 expression in cancer tissue with qRT-PCR. It was found that both genes expression was higher in cancer tissue than in adjacent tissue (Fig 1A), which is consistent with previous report by Liang et al and Lidgren et al [13,14].Then we evaluated the expression of JMJD1A in cancer tissue in 10 RCC patients and found that JMJD1A also was upregulated (Fig 1A).…”

Section: Resultssupporting

confidence: 81%

The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma

Guo

Shi²,

Sun³

et al. 2011

neo

View full text Add to dashboard Cite

Background: Hypoxia-inducible factor 1α has been shown to play a central role in RCC tumorigenesis by acting as a transcription factor. Histone demethylase JMJD1A is an iron-and 2-oxoglutarate-dependent dioxygenase which catalyze the demethylation of mono-and dimethylated H3K9. JMJD1A can be upregulated by hypoxia via HIF-1 and associated with cancer.The expression of JMJD1A was determined in 10 kidney cancer tissue and adjacent tissue by quantitative polymerase chain reaction, western blotting and immunohistochemistry. Furthermore, the expression of JMJD1A was investigated in cell line 786-0 through adding nickle or cobalt ion to mimic hypoxic environment.The expression of JMJD1A was higher in cancer tissue than adjacent tissue, and in hypoxic environment than normal environment. In cancer tissue, the JMJD1A mainly located around blood vessels which indicated that JMJD1A is involved tumor angiogenesis. Conclusion: the increased expression of JMJD1A might be associated with the progression of kidney cancer.

show abstract

Section: Resultssupporting

confidence: 81%

The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma

Guo

Shi²,

Sun³

et al. 2011

neo

View full text Add to dashboard Cite

show abstract

“…Previous studies have shown that EMMPRIN/CD147, through multiple pathways and mechanisms, stimulates adjacent fibroblasts to produce matrix metalloproteinases, and thus promotes survival, invasion and metastasis of tumor cells (13,(18)(19)(20)(21)(22)(23)36). Indeed, EMMPRIN/CD147 expression is correlated significantly with the stage of clinicopathology in thyroid carcinoma (9), adenocarcinomas (7), esophageal squamous cell carcinomas (37) and prostate cancer (14).…”

Section: Discussionmentioning

confidence: 92%

“…EMMPRIN/CD147 is a highly glycosylated transmembrane protein belonging to the immunoglobulin superfamily 34 and is widely presented and/or overexpressed on the membrane surface of various malignant tumor cells (7,8,(10)(11)(12)(13)(14)(15)(16)(17). Due to its close association with pathological classification and overall survival analysis, EMMPRIN/CD147 has been potentially suggested as a prognostic factor in certain types of malignant tumors (7,8,10,(12)(13)(14)(15)17,(21)(22)(23)(24). In the present study, our results indicated that EMMPRIN/CD147 was expressed not only in all three human osteosarcoma cell lines, but also in the cell membrance and cytoplasm of osteosarcoma tissues from the majority of patients pathologically diagnosed with osteosarcoma at grade IIA or above.…”

Section: Discussionmentioning

confidence: 99%

“…EMMPRIN/CD147 promotes survival, invasion and metastasis of tumor cells through multiple pathways and mechanisms, including the functional loss of p53, a tumor suppressor (18), upregulated expression of vascular endothelial growth factor (VEGF) (13,(19)(20)(21), disruption of transforming growth factor-β1 (TGF-β1), a growth-modulating factor (22), and regulation of the urokinase-type plasminogen activation (uPA) system of serine proteases (23). Therefore, EMMPRIN/CD147 has been suggested potentially as a prognostic biomarker for certain types of tumors and as a therapeutic target (24).…”

Section: Introductionmentioning

confidence: 99%

“…Extracellular matrix metalloproteinase inducer (EMMPRIN, also known as CD147, EMMPRIN/CD147) is a highly glycosylated transmembrane protein and is abundantly expressed on the membrane surface of various tumor cells, including non-small cell lung cancer (NSCLC) (7), macrophage-like lymphoid neoplasm P388D1 cells (8), thyroid carcinoma (9), primary cutaneous malignant melanoma (10), intrahepatic cholangiocarcinoma (11), colorectal/gastric cancer (12), renal cell carcinoma (13), prostate cancer (14), cervical cancer (15), epithelial ovarian cancer (16) and breast carcinoma (17). EMMPRIN/CD147 promotes survival, invasion and metastasis of tumor cells through multiple pathways and mechanisms, including the functional loss of p53, a tumor suppressor (18), upregulated expression of vascular endothelial growth factor (VEGF) (13,(19)(20)(21), disruption of transforming growth factor-β1 (TGF-β1), a growth-modulating factor (22), and regulation of the urokinase-type plasminogen activation (uPA) system of serine proteases (23).…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Lü

Kim

et al. 2012

Oncology Letters

View full text Add to dashboard Cite

Abstract. Osteosarcoma is the most common primary malignant bone tumor in children and adolescents. Recent studies have shown that extracellular matrix metalloproteinase inducer (EMMPRIN/CD147) promotes adhesion, invasion and metastasis of malignant tumor cells. The aim of this study was to investigate the impact of EMMPRIN/CD147 expression on prognosis and its correlation with clinicopathological characteristics in patients with osteosarcoma. The expression of EMMPRIN/CD147 in 55 surgical specimens from patients with osteosarcoma at stage IIA or above, 15 non-tumor rib bone tissues, three human osteosarcoma cell lines (Saos-2, U-2OS and MG-63), the human osteoblast cell line HOB and the malignant melanoma cell line A375 were examined by immunohistochemistry, western blot analysis and ELISA, respectively. The potential association of the levels of EMMPRIN/CD147 expression in osteosarcoma specimens with the overall survival of patients was statistically analyzed. We found that the EMMPRIN/CD147 was expressed in 45 out of 55 osteosarcomas, with immunoreactivity primarily within the membrane and cytoplasm of tumor cells, but not in the non-tumor bone tissues. We also observed that EMMPRIN/CD147 was expressed in Saos-2, U-2OS, MG-63 and A375, but not in HOB cells. The levels of EMMPRIN/CD147 expression correlated positively with the pathological degree of osteosarcoma and negatively with the survival period of patients with osteosarcoma. The expression of EMMPRIN/CD147 is a potential factor in the development and prognosis of osteosarcoma and may be a novel therapeutic target of human osteosarcoma.

show abstract

Expression of CD147 is associated with prostate cancer progression

Zhong

Liang

Lin

et al. 2011

Intl Journal of Cancer

Self Cite

View full text Add to dashboard Cite

Novel molecular markers that are associated with prostate cancer (PCa) progression will provide valuable information in the diagnosis and treatment of the disease. Extracellular matrix metalloproteinase inducer (CD147) has been demonstrated to be involved in tumor invasion, metastasis, growth and survival. In our study, we examined whether the expression of CD147 can be used as a prognostic marker for predicting PCa progression. Tissue samples from 240 patients who received radical prostatectomy for PCa were obtained. CD147 expression in these samples was evaluated using immunohistochemical staining with a monoclonal antibody specifically against CD147. Increased expression of CD147 was correlated with higher Gleason scores (GS), positive surgical margin, prostate-specific antigen (PSA) failure, metastasis and reduced overall survival. Both univariate Cox regression analysis and multivariate analysis including competing biological variables demonstrated that increased CD147 expression was associated with increased risk for reduced PSA failure-free, metastasis-free and overall survival. Kaplan-Meier survival curves showed that the CD147 overexpression was a significant predictor for the PSA failurefree, metastasis-free and the overall survival in both pT2 and pT3 PCa patients. More significantly, higher expression of CD147 can serve as an independent prognostic predictor for PSA failure-free survival in PCa patients when they are stratified by GS. Our study results demonstrate the involvement of CD147 in PCa progression and suggest its potential role as an independent predictor of biochemical recurrence, development of metastasis and reduced overall survival in PCa.Prostate cancer (PCa) is one of the most common cancers and the second leading cause of cancer death in men. 1 Although patients with localized PCa can often be successfully treated with radical prostatectomy or radiation therapy, PCa deaths are usually the results of hormone refractory and metastatic disease. It is often difficult to identify patients who will progress, recur and require additional treatments. PCa prognosis varies significantly in patients according to clinical stage and pathological grade. More sensitive PCa novel molecular markers that are associated with biological aggressiveness and providing valuable information in the diagnosis and treatment of the disease are of particular importance. Currently, effective treatment of metastatic disease is one of the major therapeutic challenges in PCa treatment. 2 In recent years, many studies have focused on identifying nomograms to include various prognostic parameters to predict PCa outcome. [3][4][5] PCa cells with high-and low-metastatic potential vary in their biological properties, such as proliferation, adhesiveness, invasiveness and motility. These variations are the results of both germ line variation between individuals and somatic alterations of genes and gene expressions in cancer

show abstract

CD147 and VEGF Expression in Advanced Renal Cell Carcinoma and Their Prognostic Value

Abstract: The expression of CD147 or VEGF may be an important feature of advanced RCC. A combined detection of CD147/VEGF coexpression may benefit us in the prediction of the prognosis of advanced RCC.

Cited by 56 publications

References 23 publications

The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma

The Expression of Histone Demethylase JMJD1A in Renal Cell Carcinoma

Expression and clinical significance of extracellular matrix metalloproteinase inducer, EMMPRIN/CD147, in human osteosarcoma

Expression of CD147 is associated with prostate cancer progression

Contact Info

Product

Resources

About